British Journal of Cancer · 2023 · 15 citations · 22 references
MedicineClinical SciencesOncologyCancer Symptom ManagementClinical Data ManagementOutcomes ResearchAdverse Event ReportingClinical Trial Data CollectionClinical TrialsClinical Trials In OncologyPatient-reported Outcome CollectionSymptom ReportingClinical Trial Outcome ReportingPatient Experience SurveysPatient Symptom ExperiencePatient-reported Adverse Event CapturePatient-reported Adverse Event ReportingPatient-reported Outcome MeasurementPatient-reported Outcome MonitoringPhase I Clinical Trials
BACKGROUND: Patient perspectives are fundamental to defining tolerability of investigational anti-neoplastic therapies in clinical trials. Phase I trials present a unique challenge in designing tools for efficiently collecting patient-reported outcomes (PROs) given the difficulty of anticipating adverse events of relevance. However, phase I trials also offer an opportunity for investigators to optimize drug dosing based on tolerability for future larger-scale trials and in eventual clinical practice. Existing tools for comprehensively capturing PROs are generally cumbersome and are not routinely used in phase I trials. METHODS: Here, we describe the creation of a tailored survey based on the National Cancer Institute's PRO-CTCAE for collecting patients' perspectives on symptomatic adverse events in phase I trials in oncology. RESULTS: We describe our stepwise approach to condensing the original 78-symptom library into a modified 30 term core list of symptoms which can be efficiently applied. We further show that our tailored survey aligns with phase I trialists' perspectives on symptoms of relevance. CONCLUSIONS: This tailored survey represents the first PRO tool developed specifically for assessing tolerability in the phase I oncology population. We provide recommendations for future work aimed at integrating this survey into clinical practice.
22
Ethan Basch, Bryce B. Reeve, Sandra A. Mitchell et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.1K citations · Full text
Pharmacy, Oncology, Cancer Control +15
Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 1K citations · Full text
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols
Melanie Calvert, Derek Kyte, Rebecca Mercieca‐Bebber et al. · JAMA · 2018 · 798 citations · Full text
Erik K. Fromme, Kristine M. Eilers, Motomi Mori et al. · Journal of Clinical Oncology · 2004 · 565 citations
Medicine, Oncology, Pharmacotherapy +16